Expression of Plasminogen Activator Inhibitor-2 is Negatively Associated with Invasive Potential in Hepatocellular Carcinoma Cells△

doi:10.1016/S1001-9294(13)60013-9

Abstract

To investigate the association between plasminogen activator inhibitor (PAI)-2 expression and invasive potential in hepatocellular carcinoma (HCC) cells.
Methods The HCC cell lines with high, low, and non-metastatic potentials, namely MHCC97-H, MHCC97-L, and SMMC-7721 respectively, were cultured in vitro. Matrigel invasion assay and Western blot of PAI-2 protein expression were conducted.
Results The number of invaded cells in MHCC97-L was significantly higher than that in SMMC-7721 (P=0.005), whereas that in MHCC97-H was higher than in MHCC97-L (P=0.017) and SMMC-7721 (P=0.001). Contrarily, PAI-2 protein expression was gradually reducing from SMMC-7721, MHCC97-L, to MHCC97-H (MHCC97-H vs. MHCC97-L, P<0.001; MHCC97-H vs. SMMC-7721, P=0.001; MHCC97-L vs. SMMC-7721, P=0.001). The Pearson’s correlation analysis revealed a significant negative association between invaded cell number and PAI-2 expression (r=-0.892, P=0.001).
Conclusion PAI-2 expression may be negatively associated with the invasive potential of HCC.

Key words: hepatocellular carcinoma, plasminogen activator inhibitor-2, invasive potential

Funding:

△Supported by the National High Technology Research and Development Program of China (863 Program, 2006AA02A308), the National Key Technologies Research and Development Program of China (2008ZX10002-016), and the Beijing Municipal Key Project (H030230280410).

Ye Jin, Li Zhou, Ke-min Jin, and Bao-cai Xing. Expression of Plasminogen Activator Inhibitor-2 is Negatively Associated with Invasive Potential in Hepatocellular Carcinoma Cells△[J].Chinese Medical Sciences Journal, 2013, 28(1): 16-19.

References 0

	Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594-606.
	Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18-29.
	Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
	El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-27.
	Au SL, Wong CC, Lee JM, et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology 2012; 56: 622-31.
	Ogawa K, Pitchakarn P, Suzuki S, et al. Silencing of connexin 43 suppresses invasion, migration and lung metastasis of rat hepatocellular carcinoma cells. Cancer Sci 2012; 103: 860-7.
	Zhu Q, Wang Z, Hu Y, et al. miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. Oncol Rep 2012; 27: 1660-8.
	Tung EK, Wong BY, Yau TO, et al. Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion. PLoS One 2012; 7: e36565.
	Gao Q, Zhao YJ, Wang XY, et al. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Res 2012; 72: 3546-56.
	Kanno K, Kanno S, Nitta H, et al. Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells. Oncol Rep 2012; 28: 867-73.
	Dass K, Ahmad A, Azmi AS, et al. Evolving role of uPA/ uPAR system in human cancers. Cancer Treat Rev 2008; 34: 122-36.
	Croucher DR, Saunders DN, Lobov S, et al. Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer 2008; 8: 535-45.
	Nordengren J, Fredstorp Lidebring M, Bendahl PO, et al. High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer. Int J Cancer 2002; 97: 379-85.
	Champelovier P, Boucard N, Levacher G, et al. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis. Urol Res 2002; 30: 301-9.
	Meijer-van Gelder ME, Look MP, Peters HA, et al. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res 2004; 64: 4563-8.
	Smith R, Xue A, Gill A, et al. High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma. World J Surg 2007; 31: 493-502.
	Zhou L, Hayashi Y, Itoh T, et al. Expression of urokinase- type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibi-tor-1 and -2 in hepatocellular carcinoma. Pathol Int 2000; 50: 392-7.
	Itoh T, Hayashi Y, Kanamaru T, et al. Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. J Gastroenterol Hepatol 2000; 15: 422-30.
	Li Y, Tang ZY, Ye SL, et al. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol 2001; 7: 630-6.
	Dong RC, Zhou RH, Lu FD, et al. Establishment of a human hepatocarcinoma cell line SMMC-7721 and initial observations on its biologic characteristics. Acad J Second Millitary Med Univ 1980; 1: 5-7.
	Varro A, Noble PJ, Pritchard DM, et al. Helicobacter pylori induces plasminogen activator inhibitor 2 in gastric epithelial cells through nuclear factor-kappaB and RhoA: implications for invasion and apoptosis. Cancer Res 2004; 64: 1695-702.
	Lobov S, Ranson M. Molecular competition between plasminogen activator inhibitors type-1 and -2 for uro- kinase: implications for cellular proteolysis and adhesion in cancer. Cancer Lett 2011; 303: 118-27.

[1]	Wanshui Yang, Hanyu Jiang, Chao Liu, Jingwei Wei, Yu Zhou, Pengyun Gong, Bin Song, Jie Tian. Multi-Omics and Its Clinical Application in Hepatocellular Carcinoma: Current Progress and Future Opportunities [J]. Chinese Medical Sciences Journal, 2021, 36(3): 173-186.
[2]	Qiong Chen,Xuefeng Yang. Research Progress in Targeted Therapy of Hepatocellular Carcinoma [J]. Chinese Medical Sciences Journal, 2021, 36(1): 57-65.
[3]	Xu Yanhong,Yang Jia,Meng Jie,Wang Han. Targeted MR Imaging Adopting T1-Weighted Ultra-Small Iron Oxide Nanoparticles for Early Hepatocellular Carcinoma: An in vitro and in vivo Study [J]. Chinese Medical Sciences Journal, 2020, 35(2): 142-150.
[4]	Zhang Xiufen, Yu Bo, Zhang Fuzheng, Guo Zijian, Li Lihua. microRNA-18a Promotes Cell Migration and Invasion Through Inhibiting Dicer l Expression in Hepatocellular Carcinoma In Vitro^△ [J]. Chinese Medical Sciences Journal, 2017, 32(1): 34-43.
[5]	Jian-bo Xu, Gang Xu, Guo-feng Chen, Dian-hua Gu, Jian-huai Zhang, Fu-zhen Qi*. Hepatocellular Carcinoma with Hypersplenic Thrombocytopenia and Situs Inversus Totalis: A Case Report [J]. Chinese Medical Sciences Journal, 2016, 31(2): 134-136.
[6]	Yao Zhang, Hua Zhang, Au Elizabeth, Xiao-qing Liu. Epidemiology of Hepatitis B and Associated Liver Diseases in China [J]. Chinese Medical Sciences Journal, 2012, 27(4): 243-248.
[7]	Ting-ting He, and Jia-he Tian*. Application of Positron Emission Tomography Molecular Probes in Hepatocellular Carcinoma Biological Imaging [J]. Chinese Medical Sciences Journal, 2011, 26(2): 113-118.

Early edition

Current issue

Archive

Specialties & Topics

Author center

Reviewer center